Growth inhibition by novel liposomes including trehalose surfactant against hepatocarcinoma cells along with apoptosis

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4727-4740

  Matsumoto, Yoko ^a   Cao, E ^a   Ueoka, Ryuichi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Hep G2; Hepatocarcinoma; HuH 7 cells; Liposome; Trehalose

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE TREHALOSE SURFACTANT; LIPOSOME; PROTEIN BAX; SURFACTANT; TREHALOSE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE POLARIZATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ULTRASOUND;

APOPTOSIS; HEP-G2; HEPATOCARCINOMA; HUH-7 CELLS; LIPOSOME; TREHALOSE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL MEMBRANE; CYTOCHROMES C; FLOW CYTOMETRY; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTO-ONCOGENE PROTEINS C-BCL-2; SURFACE-ACTIVE AGENTS; TREHALOSE; TUMOR CELLS, CULTURED;

EID: 84891347731     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003
2. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
4. Llovet JM, Ricci S, Maxxaferro V, Hilgard P, Gane E, Blanc JF, Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liag H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: Phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
6. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
7. Graybill JR, Craven PC, Taylor RL, Williams DM and Magee WE: Treatment of murine cryptococcosis with liposomes-associated amphotericin B. J Infect Dis 145: 748-752, 1982.
8. Ueoka R, Matsumoto Y, Moss RA, Swarup S, Sugii A, Harada K, Kikuchi J and Murakami Y: Membrane matrix for the hydrolysis of amino acid esters with marked enantioselectivity. J Am Chem Soc 110: 1588-1595, 1988.
9. Matsumoto Y, Kato T, Iseki S, Suzuki H, Nakano K, Iwahara M and Ueoka R: Remarkably enhanced inhibitory effects of hybrid liposomes on the growth of tumor cells in vitro. Bioorg Med Chem Lett 9: 1937-1940, 1999.
10. Matsumoto Y, Iwamoto Y, Matsushita T and Ueoka R: Novel mechanism of hybrid liposomes-induced apoptosis in human tumor cells. Int J Cancer 115: 377-382, 2005.
11. Iwamoto Y, Matsumoto Y and Ueoka R: Induction of apoptosis of human lung carcinoma cells by hybrid liposomes containing polyoxyethylenedodecyl ether. Int J Pharm 292: 231-239, 2005.
12. Shimoda S, Ichihara H, Matsumoto Y and Ueoka R: Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo. Int J Pharm 372: 162-168, 2009.
13. Ichihara H, Ueno J, Umebayashi M, Matsumoto Y and Ueoka R: Chemotherapy with hybrid liposomes for acute lymphatic leukemia leading to apoptosis in vivo. Int J Pharm 406: 173-178, 2011.
14. Komizu Y, Matsumoto Y and Ueoka R: Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis. Bioorg Med Chem Lett 16: 6131-6134, 2006.
15. Komizu Y, Nakata S, Goto, K, Matsumoto Y and Ueoka R: Membrane-targeted nanotherapy with hybrid liposomes for colon tumor cells leading to apoptosis. ACS Med Chem 2: 275-279, 2011.
16. Ichihara H, Nagami H, Kiyokawa T, Matsumoto Y and Ueoka R: Chemotherapy using hybrid liposomes along with induction of apoptosis. Anticancer Res 28: 1187-1196, 2008.
17. Umebayashi M, Makizono T, Ichihara H, Matsumoto Y, Ueoka R: Inhibitory effects of cationic hybrid liposomes on the growth of human renal carcinoma. Anticancer Res 30: 327-338, 2010.
18. Gabius HJ, Engelhardt R, Hellman T, Midox P, Monsigny M, Nagel GA and Vehmeyer K: Charaterization of membrane lectins in human colon carcinoma cells by flow cytofluorometry, drug targeting and affinity chromatography. Anticaner Res 7: 109-124, 1987.
19. Varki A: Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3: 97-113, 1993.
20. Uedaira H, Okouchi S, Tsuda S and Uedaira H: Hydration of glucose and galactose derivatives. Bull Chem Soc Jpn 74: 1857-1869, 2001.
21. Yamazaki N, Jigami Y, Gabius HJ and Kojima S: Preparation and characterization of neoglycoprotein-liposomes conjugates: A promising approach to developing drug delivery materials applying sugar chain ligands. Trends Glycosci Glycotechnol 13: 319-331, 2001.
22. Matsumoto Y, Kato T, Suzuki H, Hirose S, Naiki Y, Hirashima M and Ueoka R: Highly specific inhibitory effects of three component hybrid liposomes including sugar surfactants on the growth of glioma cells. Bioorg Med Chem Lett 10: 2617-2619, 2000.
23. Matsumoto Y, Tanaka Y, Goto K, Ueoka R: Specific fixed aqueous layer of three component hybrid liposomes related to inhibition of hepatoma cell growth. Chem. Lett 18: 118-119, 2008.
24. Shimada K, Miyagichita A, Sadzuka Y, Nozawa Y, Mochizuki Y, Oshima H and Hirota S: Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes. J Drug Target 3: 283-297, 1995.
25. Azumi T and McGlynn SP: Polarization of the luminescence of phenanthrene. J Chem Phys 37: 2413-2420, 1962.
26. Nagamura T, Mihara S, Okahata Y, Kunitake T and Matsuo T: NMR and fluorescence study on self-assembling behavior of dialkyldimethylammonium salts in aqueous solutions. Ber Bunsenges Phys Chem 82: 1093-1098, 1978.
27. Ishiyama M, Shiga M, Sasamoto Y, Machiguchi M and He P: A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 41: 1118-1122, 1993.
28. Eskes R, Antonsson B, Sand AO-, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A and Martinou JC: BAX-induced cytochrome c release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ions. J Cell Biol 143: 217-224, 1998.
29. Matsumoto Y, Cao E and Ueoka R: Novel liposomes composed of dimyristoylphosphatidylcholine and trehalose surfactants inhibit the growth of tumor cells along with apoptosis. Biol Pharm Bull 36: 1258-1262, 2013.
30. Damadian R, Zaner K, Hor D and Dimaio T: Human tumors by NMR. Physiol Chem Phys 5: 381-402, 1973.
31. Inbar M: Fluidity of membrane lipids: A single-cell analysis of mouse normal lymphocytes and malignant lymphoma cells. FEBS Lett 67: 180-185, 1976.
32. Shinitzky M: Membrane fluidity in malignancy. Adversative and recuperative. Biochim Biophys Acta 738: 251-261,1984.